AllianceBernstein’s Syndax Pharmaceuticals SNDX Stock Holding History

AllianceBernstein’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.06M	Buy	288,567 +193,687	+204%	+$4.21M	﹤0.01%	1449
2025 Q4	$1.99M	Sell	94,880 -31,769	-25%	-$554K	﹤0.01%	2008
2025 Q3	$1.95M	Buy	126,649 +9,000	+8%	+$118K	﹤0.01%	2018
2025 Q2	$1.1M	Sell	117,649 -51,035	-30%	-$562K	﹤0.01%	2236
2025 Q1	$2.07M	Buy	168,684 +83,434	+98%	+$1.18M	﹤0.01%	1879
2024 Q4	$1.13M	Hold	85,250	–	–	﹤0.01%	2273
2024 Q3	$1.64M	Hold	85,250	–	–	﹤0.01%	2071
2024 Q2	$1.75M	Buy	85,250 +7,790	+10%	+$163K	﹤0.01%	2029
2024 Q1	$1.84M	Hold	77,460	–	–	﹤0.01%	1962
2023 Q4	$1.67M	Hold	77,460	–	–	﹤0.01%	2031
2023 Q3	$1.12M	Sell	77,460 -53,870	-41%	-$1.02M	﹤0.01%	2176
2023 Q2	$2.75M	Buy	131,330 +22,510	+21%	+$469K	﹤0.01%	1727
2023 Q1	$2.3M	Hold	108,820	–	–	﹤0.01%	1789
2022 Q4	$2.77M	Hold	108,820	–	–	﹤0.01%	1724
2022 Q3	$2.62M	Buy	108,820 +66,420	+157%	+$1.49M	﹤0.01%	1714
2022 Q2	$816K	Buy	42,400 +10,100	+31%	+$168K	﹤0.01%	2453
2022 Q1	$561K	Buy	32,300 +100	+0.3%	+$1.68K	﹤0.01%	2627
2021 Q4	$705K	Hold	32,200	–	–	﹤0.01%	2601
2021 Q3	$615K	Hold	32,200	–	–	﹤0.01%	2680
2021 Q2	$553K	Buy	32,200 +4,700	+17%	+$86.1K	﹤0.01%	2775
2021 Q1	$615K	Hold	27,500	–	–	﹤0.01%	2588
2020 Q4	$612K	Sell	27,500 -6,200	-18%	-$129K	﹤0.01%	2498
2020 Q3	$497K	Hold	33,700	–	–	﹤0.01%	2535
2020 Q2	$499K	Buy	33,700 +5,400	+19%	+$82.2K	﹤0.01%	2611
2020 Q1	$310K	Buy	28,300 +11,300	+66%	+$106K	﹤0.01%	2605
2019 Q4	$149K	Hold	17,000	–	–	﹤0.01%	2981
2019 Q3	$127K	Buy	17,000 +2,300	+16%	+$20.9K	﹤0.01%	3043
2019 Q2	$137K	Buy	14,700 +1,000	+7%	+$7.29K	﹤0.01%	3031
2019 Q1	$72K	Hold	13,700	–	–	﹤0.01%	3056
2018 Q4	$61K	Hold	13,700	–	–	﹤0.01%	3042
2018 Q3	$111K	Hold	13,700	–	–	﹤0.01%	3069
2018 Q2	$96K	Buy	13,700 +3,500	+34%	+$34.3K	﹤0.01%	3056
2018 Q1	$145K	Hold	10,200	–	–	﹤0.01%	2924
2017 Q4	$89K	Buy	+10,200	New	+$101K	﹤0.01%	2971

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

AllianceBernstein's SNDX Position: Q1 2026 in Review

AllianceBernstein increased its Syndax Pharmaceuticals (SNDX) stake by 204% in Q1 2026, buying an estimated $4.21M and bringing the position to 288,567 shares worth $6.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1449.

AllianceBernstein first reported a position in SNDX in Q4 2017 and has held it in 34 quarters since. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

AllianceBernstein held 288,567 shares of Syndax Pharmaceuticals worth $6.06M as of Q1 2026.
AllianceBernstein bought 193,687 Syndax Pharmaceuticals shares in Q1 2026, an estimated $4.21M.
Syndax Pharmaceuticals made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #1449 holding.
AllianceBernstein first reported a position in Syndax Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.